EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte Studie

Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis

Geert D'Haens, Marla Dubinsky, Taku Kobayashi, Peter M Irving, Stefanie Howaldt, Juris Pokrotnieks, Kathryn Krueger, Janelle Laskowski, Xingyuan Li, Trevor Lissoos, Joe Milata, Nathan Morris und 5 weitere

New England Journal of Medicine · 29.06.2023 · 388 (26) · 2444-2455

DOI: 10.1056/nejmoa2207940 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, erschienen am 29.06.2023. Verfasst von Geert D'Haens und 16 weiteren Autor:innen. Beteiligte Einrichtung: From the Department of Gastroenterology and Hepatology, Amsterdam University Medical Centers, Amsterdam (G.D.); Dr. Henry D. Janowitz Division of Gas…. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Anti-Inflammatory Agents, Non-Steroidal. Die Arbeit wurde bisher 377-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeAnti-Inflammatory Agents, Non-SteroidalAdultHumansDouble-Blind MethodHerpes ZosterInduction ChemotherapyMaintenance ChemotherapyOpportunistic InfectionsRemission InductionAdministration, IntravenousSubcutaneous AbsorptionAntibodies, Monoclonal, Humanized

Substanzen

Anti-Inflammatory Agents, Non-SteroidalmirikizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • From the Department of Gastroenterology and Hepatology, Amsterdam University Medical Centers, Amsterdam (G.D.); Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York (M.D.…

ORCID-Profile: Bruce E Sands

Förderung

  • Eli Lilly and Company

Zitieren

APA

D'Haens, G., Dubinsky, M., Kobayashi, T., Irving, P. M., Howaldt, S., Pokrotnieks, J., Krueger, K., Laskowski, J., Li, X., Lissoos, T., Milata, J., Morris, N., Arora, V., Milch, C., Sandborn, W., Sands, B. E., & LUCENT Study Group (2023). Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis. New England Journal of Medicine, 388(26), 2444-2455. https://doi.org/10.1056/nejmoa2207940

Vancouver

D'Haens G, Dubinsky M, Kobayashi T, Irving PM, Howaldt S, Pokrotnieks J, et al. Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis. New England Journal of Medicine. 2023;388(26):2444-2455. doi:10.1056/nejmoa2207940

BibTeX
@article{DHaens2023,
  author = {D'Haens, Geert and Dubinsky, Marla and Kobayashi, Taku and Irving, Peter M and Howaldt, Stefanie and Pokrotnieks, Juris and Krueger, Kathryn and Laskowski, Janelle and Li, Xingyuan and Lissoos, Trevor and Milata, Joe and Morris, Nathan and Arora, Vipin and Milch, Catherine and Sandborn, William and Sands, Bruce E and LUCENT Study Group, LUCENT Study Group},
  title = {Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis},
  journal = {New England Journal of Medicine},
  year = {2023},
  volume = {388},
  number = {26},
  pages = {2444--2455},
  doi = {10.1056/nejmoa2207940}
}
Kostenlos starten →